DE602004004156D1 - Verbindungen, verfahren und formulierungen zur oralen verabreichung einer glucagon like peptide (glp)-1-verbindung oder eines am melanocortin-4-rezeptor (mc4) als agonist wirkenden peptids - Google Patents
Verbindungen, verfahren und formulierungen zur oralen verabreichung einer glucagon like peptide (glp)-1-verbindung oder eines am melanocortin-4-rezeptor (mc4) als agonist wirkenden peptidsInfo
- Publication number
- DE602004004156D1 DE602004004156D1 DE602004004156T DE602004004156T DE602004004156D1 DE 602004004156 D1 DE602004004156 D1 DE 602004004156D1 DE 602004004156 T DE602004004156 T DE 602004004156T DE 602004004156 T DE602004004156 T DE 602004004156T DE 602004004156 D1 DE602004004156 D1 DE 602004004156D1
- Authority
- DE
- Germany
- Prior art keywords
- compounds
- glp
- methods
- formulations
- peptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D263/48—Nitrogen atoms not forming part of a nitro radical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
- C07D249/06—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles with aryl radicals directly attached to ring atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D277/24—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/01—Five-membered rings
- C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
- C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
- C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US49653703P | 2003-08-20 | 2003-08-20 | |
US496537P | 2003-08-20 | ||
PCT/US2004/024386 WO2005019184A1 (en) | 2003-08-20 | 2004-08-18 | Compounds, methods and formulations for the oral delivery of a glucagon like peptide (glp)-1 compound or an melanocortin 4 receptor (mc4) agonist peptide |
Publications (2)
Publication Number | Publication Date |
---|---|
DE602004004156D1 true DE602004004156D1 (de) | 2007-02-15 |
DE602004004156T2 DE602004004156T2 (de) | 2007-10-11 |
Family
ID=41134571
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE602004004156T Active DE602004004156T2 (de) | 2003-08-20 | 2004-08-18 | Verbindungen, verfahren und formulierungen zur oralen verabreichung einer glucagon like peptide (glp)-1-verbindung oder eines am melanocortin-4-rezeptor (mc4) als agonist wirkenden peptids |
Country Status (8)
Country | Link |
---|---|
US (3) | US7662771B2 (de) |
EP (1) | EP1658273B1 (de) |
JP (1) | JP4767850B2 (de) |
AT (1) | ATE350369T1 (de) |
CA (1) | CA2532026C (de) |
DE (1) | DE602004004156T2 (de) |
ES (1) | ES2278346T3 (de) |
WO (1) | WO2005019184A1 (de) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2532026C (en) * | 2003-08-20 | 2012-04-17 | Eli Lilly And Company | Compounds, methods and formulations for the oral delivery of a glucagon like peptide (glp)-1 compound or an melanocortin 4 receptor (mc4) agonist peptide |
ES2286679T3 (es) * | 2003-08-20 | 2007-12-01 | Eli Lilly And Company | Compuestos, procedimientos y formulaciones para la liberacion oral de un compuesto de peptido de tipo glucagon (glp)-1 o un peptido agonist a del receptor de melanocortina 4 (mc4). |
PL3354273T3 (pl) | 2005-07-08 | 2021-10-11 | Ipsen Pharma | Ligandy receptora melanokortyny |
US8349797B2 (en) | 2005-07-08 | 2013-01-08 | Ipsen Pharma S.A.S. | Ligands of melanocortin receptors |
AU2006338265B2 (en) | 2005-08-18 | 2011-04-14 | Synta Pharmaceuticals Corp. | Triazole compounds that modulate HSP90 activity |
EP2057112B1 (de) * | 2006-08-31 | 2018-12-19 | Emisphere Technologies, Inc. | Verbindungen und zusammensetzungen zur wirkstofffreisetzung |
CA2677481C (en) | 2007-02-08 | 2015-07-07 | Synta Pharmaceuticals Corp. | Triazole compounds that modulate hsp90 activity |
US8748469B2 (en) | 2008-04-24 | 2014-06-10 | Newlink Genetics Corporation | IDO inhibitors |
JPWO2009139181A1 (ja) | 2008-05-15 | 2011-09-15 | 大正製薬株式会社 | 4員環構造を有する10a−アザライド化合物 |
WO2011045418A1 (en) * | 2009-10-16 | 2011-04-21 | Dsm Ip Assets B.V. | Azido alkanoic acids and derivatives thereof in feed for reducing methane formation emanating from the digestive activities of ruminants |
RS61504B1 (sr) | 2014-10-24 | 2021-03-31 | Takeda Pharmaceuticals Co | Jedinjenja heteroarila za lečenje oftalmičkih bolesti |
CN115925679A (zh) | 2014-12-24 | 2023-04-07 | 株式会社Lg化学 | 作为gpr120激动剂的联芳基衍生物 |
WO2016168388A2 (en) | 2015-04-14 | 2016-10-20 | Palatin Technologies, Inc. | Therapies for obesity, diabetes and related indications |
CN107163011B (zh) * | 2017-05-27 | 2019-10-01 | 上海应用技术大学 | 3-(3,4,5-三甲氧基苯甲酰)-苯并呋喃类微管蛋白抑制剂及其制备方法和用途 |
CN113248455A (zh) * | 2021-05-25 | 2021-08-13 | 湖北科技学院 | 一种3,5-二取代异噁唑类衍生物及其合成方法 |
Family Cites Families (48)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2423709A (en) * | 1947-07-08 | X-aryl thiazole | ||
US3412193A (en) | 1965-12-13 | 1968-11-19 | American Cyanamid Co | 11-(4-methyl-1-piperazinyl)dibenz[b, f][1, 4]oxazepines or thiazepines for controlling fertility |
US3578671A (en) | 1967-11-06 | 1971-05-11 | Wyeth John & Brother Ltd | Oxazoles |
FR2374910A1 (fr) | 1976-10-23 | 1978-07-21 | Choay Sa | Preparation a base d'heparine, comprenant des liposomes, procede pour l'obtenir et medicaments contenant de telles preparations |
AU610083B2 (en) | 1986-08-18 | 1991-05-16 | Clinical Technologies Associates, Inc. | Delivery systems for pharmacological agents |
EP0451790A1 (de) * | 1990-04-12 | 1991-10-16 | Hoechst Aktiengesellschaft | 3,5-disubstituierte 2-Isoxazoline und Isoxazole, Verfahren zu deren Herstellung, diese enthaltende Mittel und ihre Verwendung |
US5541155A (en) | 1994-04-22 | 1996-07-30 | Emisphere Technologies, Inc. | Acids and acid salts and their use in delivery systems |
US5693338A (en) | 1994-09-29 | 1997-12-02 | Emisphere Technologies, Inc. | Diketopiperazine-based delivery systems |
US5643957A (en) | 1993-04-22 | 1997-07-01 | Emisphere Technologies, Inc. | Compounds and compositions for delivering active agents |
CN1151836C (zh) | 1995-03-31 | 2004-06-02 | 艾米斯菲尔技术有限公司 | 用作传送活性剂的化合物和组合物 |
US5989539A (en) | 1995-03-31 | 1999-11-23 | Emisphere Technologies, Inc. | Compounds and compositions for delivering active agents |
US6001347A (en) | 1995-03-31 | 1999-12-14 | Emisphere Technologies, Inc. | Compounds and compositions for delivering active agents |
US5965121A (en) | 1995-03-31 | 1999-10-12 | Emisphere Technologies, Inc. | Compounds and compositions for delivering active agents |
US5650386A (en) | 1995-03-31 | 1997-07-22 | Emisphere Technologies, Inc. | Compositions for oral delivery of active agents |
US5866536A (en) | 1995-03-31 | 1999-02-02 | Emisphere Technologies, Inc. | Compounds and compositions for delivering active agents |
US5820881A (en) | 1995-04-28 | 1998-10-13 | Emisphere Technologies, Inc. | Microspheres of diamide-dicarboxylic acids |
GB9604242D0 (en) * | 1996-02-28 | 1996-05-01 | Glaxo Wellcome Inc | Chemical compounds |
US5995503A (en) * | 1996-06-12 | 1999-11-30 | Bay Networks, Inc. | Method and apparatus for providing quality of service routing in a network |
ATE338754T1 (de) * | 1996-07-19 | 2006-09-15 | Takeda Pharmaceutical | Heterocyclische verbindungen, ihre herstellung und verwendung |
ATE383169T1 (de) * | 1997-02-07 | 2008-01-15 | Emisphere Tech Inc | Komponente und zusammensetzungen zur verabreichung von wirkstoffen |
US6313088B1 (en) | 1997-02-07 | 2001-11-06 | Emisphere Technologies, Inc. | 8-[(2-hydroxy-4-methoxy benzoyl) amino]-octanoic acid compositions for delivering active agents |
WO2000040203A2 (en) | 1999-01-08 | 2000-07-13 | Emisphere Technologies, Inc. | Polymeric delivery agents and delivery agent compounds |
ES2251976T3 (es) * | 1999-02-11 | 2006-05-16 | Emisphere Technologies, Inc. | Compuestos y composiciones de oxadiazol para aportar agentes activos. |
EP1163209A4 (de) | 1999-02-26 | 2004-12-29 | Emisphere Tech Inc | Verbindungen und zusammensetzungen zur bereitstellung aktiver wirkstoffe |
DE60017888T2 (de) | 1999-04-05 | 2006-01-19 | Emisphere Technologies, Inc. | Dinatrium-salze, monohydrate und ethanol-solvate |
SE9902987D0 (sv) * | 1999-08-24 | 1999-08-24 | Astra Pharma Prod | Novel compounds |
AR035016A1 (es) * | 1999-08-25 | 2004-04-14 | Takeda Chemical Industries Ltd | Composicion de azol promotor de produccion/secrecion de neurotrofina, compuesto prodroga del mismo, composicion farmaceutica que lo comprende y uso del mismo para preparar esta ultima. |
AU2622301A (en) | 1999-11-05 | 2001-05-14 | Emisphere Technologies, Inc. | Phenyl amine carboxylic acid compounds and compositions for delivering active agents |
DE60038183T2 (de) | 1999-12-16 | 2009-02-19 | Emisphere Technologies, Inc. | Verbindungen und zusammensetzungen zur abgabe aktiver wirkstoffe |
JP4879433B2 (ja) | 2000-01-13 | 2012-02-22 | エミスフェアー・テクノロジーズ・インク | 活性剤を送達するための化合物および組成物 |
UA80248C2 (en) | 2000-06-29 | 2007-09-10 | Compounds and compositions for delivering active agents | |
CA2420178A1 (en) * | 2000-08-23 | 2002-03-07 | Eli Lilly And Company | Oxazolyl-aryloxyacetic acid derivatives and their use as ppar agonists |
US6930120B2 (en) * | 2000-08-23 | 2005-08-16 | Eli Lilly And Company | Oxazolyl-arylproplonic acid derivatives and their use as ppar agonists |
US20020103192A1 (en) * | 2000-10-26 | 2002-08-01 | Curtin Michael L. | Inhibitors of histone deacetylase |
JP4148672B2 (ja) | 2000-11-17 | 2008-09-10 | 武田薬品工業株式会社 | イソオキサゾール誘導体 |
WO2002040458A1 (fr) * | 2000-11-17 | 2002-05-23 | Takeda Chemical Industries, Ltd. | Derives d'isoxazole |
US6578671B2 (en) * | 2000-12-18 | 2003-06-17 | Raymond Shen | Method and system for the automated exchange of merchandise |
CA2432429A1 (en) * | 2000-12-21 | 2002-06-27 | Glaxo Group Limited | Macrolide antibiotics |
JP4248244B2 (ja) | 2001-02-14 | 2009-04-02 | 明治製菓株式会社 | 12、13位変換新規16員環マクロライド誘導体 |
GB2373186A (en) | 2001-02-23 | 2002-09-18 | Astrazeneca Ab | Pharmaceutical combinations of a CCR3 antagonist and a compound which is usefulreatment of asthma, allergic disease or inflammation |
WO2002096359A2 (en) | 2001-05-30 | 2002-12-05 | Merck & Co., Inc. | Piperazine pentanamide hiv protease inhibitors |
KR100957516B1 (ko) * | 2001-08-15 | 2010-05-14 | 이코스 코포레이션 | 2h-프탈라진-1-온 및 이것의 사용 방법 |
WO2003057215A1 (fr) | 2001-12-28 | 2003-07-17 | Takeda Chemical Industries, Ltd. | Accelerateur de production/secretion de facteur neurotrophique |
CN1332711C (zh) | 2002-02-20 | 2007-08-22 | 埃米球科技有限公司 | 施用glp-1分子的方法 |
JP2004277397A (ja) | 2002-05-24 | 2004-10-07 | Takeda Chem Ind Ltd | 1,2−アゾール誘導体 |
AU2003241173A1 (en) * | 2002-05-24 | 2003-12-12 | Takeda Pharmaceutical Company Limited | 1,2-azole derivatives with hypoglycemic and hypolipidemic activity |
EA200600055A1 (ru) | 2003-06-19 | 2006-08-25 | Эли Лилли Энд Компани | Агонисты рецептора меланокортина 4 (мк4 ) и их применение |
CA2532026C (en) * | 2003-08-20 | 2012-04-17 | Eli Lilly And Company | Compounds, methods and formulations for the oral delivery of a glucagon like peptide (glp)-1 compound or an melanocortin 4 receptor (mc4) agonist peptide |
-
2004
- 2004-08-18 CA CA2532026A patent/CA2532026C/en not_active Expired - Fee Related
- 2004-08-18 ES ES04779446T patent/ES2278346T3/es active Active
- 2004-08-18 EP EP04779446A patent/EP1658273B1/de not_active Not-in-force
- 2004-08-18 US US10/566,342 patent/US7662771B2/en active Active
- 2004-08-18 DE DE602004004156T patent/DE602004004156T2/de active Active
- 2004-08-18 AT AT04779446T patent/ATE350369T1/de not_active IP Right Cessation
- 2004-08-18 WO PCT/US2004/024386 patent/WO2005019184A1/en active IP Right Grant
- 2004-08-18 JP JP2006523865A patent/JP4767850B2/ja not_active Expired - Fee Related
-
2009
- 2009-12-11 US US12/636,244 patent/US8552039B2/en active Active
-
2013
- 2013-08-20 US US13/971,680 patent/US8765796B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
CA2532026C (en) | 2012-04-17 |
US7662771B2 (en) | 2010-02-16 |
WO2005019184A1 (en) | 2005-03-03 |
US8552039B2 (en) | 2013-10-08 |
EP1658273B1 (de) | 2007-01-03 |
EP1658273A1 (de) | 2006-05-24 |
US20080214448A1 (en) | 2008-09-04 |
US20100120876A1 (en) | 2010-05-13 |
US20140031287A1 (en) | 2014-01-30 |
US8765796B2 (en) | 2014-07-01 |
CA2532026A1 (en) | 2005-03-03 |
ATE350369T1 (de) | 2007-01-15 |
DE602004004156T2 (de) | 2007-10-11 |
JP2007502816A (ja) | 2007-02-15 |
ES2278346T3 (es) | 2007-08-01 |
JP4767850B2 (ja) | 2011-09-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE602004004156D1 (de) | Verbindungen, verfahren und formulierungen zur oralen verabreichung einer glucagon like peptide (glp)-1-verbindung oder eines am melanocortin-4-rezeptor (mc4) als agonist wirkenden peptids | |
DE602004006279D1 (de) | Verbindungen, verfahren und formulierungen zur oralen verabreichung einer glucagonartigen peptid (glp)-1-verbindung oder eines melanocortin-4-rezeptor-(mc4-)agonistschen peptids | |
ATE541582T1 (de) | Stabilisierte pharmazeutische glp-1 peptid zusammensetzungen | |
BRPI0607762B8 (pt) | análogos de glp-1, composição farmacêutica contendo os mesmos e uso de um composto | |
BRPI0417717A (pt) | composto, composição farmacêutica, e, uso de um composto | |
BRPI0417684A (pt) | composto, composição farmacêutica, e, uso de um composto | |
EA200700312A1 (ru) | Композиции для доставки лекарственных средств с высокой водорастворимостью | |
DE60030741D1 (de) | Chinazoline verbindungen als heilmittel | |
PH12012501351A1 (en) | Synthesis of eporthilones, intermediates thereto, analogues and uses thereof | |
EP2374812A3 (de) | 4-amino-4-oxobutanoyl-Peptide als Hemmer viraler Replikation | |
EA200600620A1 (ru) | Набор для ингаляции с ингаляционным порошком, содержащим тиотропий | |
CL2007003299A1 (es) | Compuestos derivados de macrociclos, inhibidores del virus de la hepatitis c; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de la hepatitis c. | |
ES2421447T3 (es) | Métodos para proteger frente a apoptosis usando lipopéptidos | |
NO20044897L (no) | Hepatitt C virus inhibitorer | |
ATE529126T1 (de) | Stabilisierte pharmazeutische peptid zusammensetzungen | |
WO2008033561A3 (en) | Click chemistry-derived cyclopeptide derivatives as imaging agents for integrins | |
MX2008001560A (es) | Nuevos compuestos analogos de la camptotecina, un procedimiento para su preparacion y composiciones farmaceuticas que los contienen. | |
UY27986A1 (es) | Nuevas quinazolinonas espirocondensadas y su uso c omo inhibidores de la fosfodiesterasa | |
EA200601408A1 (ru) | Композиция, способы и применения нового семейства пептидов | |
PL376176A1 (en) | Solid preparation | |
ECSP045493A (es) | Nuevas composiciones farmacéuticas que contienen flibanserina polimorfo a | |
DE602004005564D1 (de) | Pharmazeutische Zusammensetzung für Thrombinpeptidderivaten | |
CY1109444T1 (el) | Φαρμακευτικη συνθεση που περιεχει κυκλικα αναλογα σωματοστατινης | |
MXPA05013758A (es) | Composiciones farmaceuticas que incluyen una antihistamina y un estimulante y uso de las mismas. | |
DE60319707D1 (de) | Pharmazeutische zusammensetzung enthaltend ein benzimidazol-derivat gemischt mit mikrokristalliner cellulose |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition | ||
8327 | Change in the person/name/address of the patent owner |
Owner name: EMISPHERE TECHNOLOGIES, INC., TARRYTOWN, N.Y., US |
|
8328 | Change in the person/name/address of the agent |
Representative=s name: KROHER, STROBEL RECHTS- UND PATENTANWAELTE, 80336 |
|
8328 | Change in the person/name/address of the agent |
Representative=s name: DR. SCHOEN & PARTNER, 80336 MUENCHEN |